We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Remote-Control Nanoparticles Deliver Drugs to Tumors

By Biotechdaily staff writers
Posted on 06 Dec 2007
Innovative nanoparticles that can be triggered to release drugs directly attacking tumors could lead to an improved diagnosis and a more targeted treatment of cancer. More...


Researchers at the Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) developed a system that consists of tiny particles that are superparamagnetic, a property that causes them to give off heat when they are exposed to a magnetic field. Tethered to these particles are active molecules, such as therapeutic drugs. Exposing the particles to a low-frequency electromagnetic field causes the particles to radiate heat that, in turn, melts the tethers and releases the drugs. The tethers in the system consist of two strands of DNA linked together through hydrogen bonds. In the presence of the magnetic field, heat generated by the nanoparticles breaks these bonds, leaving one strand attached to the particle and allowing the other to float away with its cargo.

To test the particles, the researchers implanted mice with a tumor- like gel saturated with nanoparticles. They placed the implanted mouse into the well of a cup-shaped electrical coil and activated the magnetic pulse. The results confirmed that without the pulse, the tethers remain unbroken. With the pulse, the tethers break and release the drugs into the surrounding tissue. The waves in this magnetic field have frequencies between 350 and 400 kilohertz—similar to radio waves. These waves pass harmlessly through the body and heat only the nanoparticles. The study was reported in the November 15, 2007, online issue of Advanced Materials.

Our overall goal is to create multifunctional nanoparticles that home to a tumor, accumulate, and provide customizable remotely activated drug delivery right at the site of the disease, said lead author Sangeeta Bhatia, M.D.,Ph.D., an associate professor in the Harvard-MIT Division of Health Sciences & Technology (HST).


Related Links:
Massachusetts Institute of Technology

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Clinical Informatics Platform
CLARION™
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.